In The News

In The News

Practical Neurology | September 05, 2018
A roundtable discussion with Chase Spurlock, PhD, IQuity; Michal Izrael, PhD, Kadimastem Ltd; Kevin Hrusovsky, Quanterix; and J. Michael Ryan, MD, Rodin Therapeutics
Washington Report | September 04, 2018
By: Kevin Hrusovsky
ALZFORUM.ORG | August 24, 2018
A lot can happen in a year.
Specialty Pharmacy Times | August 17, 2018
A new technology allows researchers to use brain biomarker neurofilament light chain (NfL) to uncover insights into the development and progression of neurological diseases, such as multiple sclerosis (MS).  
MD+DI | March 21, 2018
Quanterix teams up with DestiNA to develop assays to detect liver toxicity in patients.
Bloomberg | February 05, 2018
Bloomberg reporter Anne Mostue interviews Kevin Hrusovsky in segment called, "The Race to Diagnose CTE in the Living"
Quartz | February 03, 2018
"What we need is collaboration among scientists, researchers, the NFL and other contact sports governing bodies to develop a blood test that can be used to monitor players’ brain health, as a blood test is a better alternative to CT scans and subjective tests that are entrenched in current protocol…
SelectScience Interview | January 29, 2018
Ralph McDade explains the importance of using ultra-sensitive immunoassays from Quanterix
SelectScience Interview | January 31, 2018
Ultrasensitive Simoa technology to advance research into tumor-derived exosomes at the University of Pittsburgh Cancer Institute, led by Theresa Whiteside, professor of pathology